Voyager Therapeutics (VYGR) Assets Average (2015 - 2026)

Voyager Therapeutics has disclosed Assets Average across 12 years of filings, most recently posting $235.8 million for Q1 2026.

• Assets Average for Q1 2026 came in at $235.8 million, down 36.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.8 million (down 36.81% YoY), and the FY2025 annual result was $322.7 million, down 13.3% from the prior year.
• Assets Average came in at $235.8 million for Q1 2026 at Voyager Therapeutics, down from $270.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $452.9 million in Q2 2024 to a low of $170.9 million in Q4 2022.
• The 5-year median for Assets Average is $305.2 million (2025), against an average of $305.9 million.
• Across the five-year window, Assets Average surged 88.96% in 2023 and tumbled 36.81% in 2026, its largest moves.
• Voyager Therapeutics' Assets Average stood at $170.9 million in 2022, then jumped by 88.96% to $323.0 million in 2023, then rose by 26.81% to $409.5 million in 2024, then sank by 34.0% to $270.3 million in 2025, then fell by 12.76% to $235.8 million in 2026.
• The last three Assets Average figures came in at $235.8 million (Q1 2026), $270.3 million (Q4 2025), and $305.2 million (Q3 2025), per Business Quant data.